Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 235


Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence.

Preisser F, Busto L, Pompe RS, Heinze A, Haese A, Graefen M, Tilki D.

Urol Oncol. 2019 Oct 2. pii: S1078-1439(19)30356-4. doi: 10.1016/j.urolonc.2019.09.005. [Epub ahead of print]


Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer.

Steurer S, Hager B, Büscheck F, Höflmayer D, Tsourlakis MC, Minner S, Clauditz TS, Hube-Magg C, Luebke AM, Simon R, Izbicki JR, Burandt E, Sauter G, Fraune C, Weidemann S, Schlomm T, Heinzer H, Haese A, Graefen M, Huland H, Heumann A.

Aging (Albany NY). 2019 Sep 25;11(18):7859-7879. doi: 10.18632/aging.102294. Epub 2019 Sep 25.


Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers.

Luebke AM, Attarchi-Tehrani A, Meiners J, Hube-Magg C, Lang DS, Kluth M, Tsourlakis MC, Minner S, Simon R, Sauter G, Büscheck F, Jacobsen F, Hinsch A, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Clauditz TS, Burandt E, Wilczak W, Höflmayer D.

Cancer Biol Med. 2019 May;16(2):319-330. doi: 10.20892/j.issn.2095-3941.2018.0384.


Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.

Preisser F, Bandini M, Nazzani S, Mazzone E, Marchioni M, Tian Z, Chun FKH, Saad F, Briganti A, Haese A, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Oncol. 2019 Mar 28. pii: S2588-9311(19)30035-5. doi: 10.1016/j.euo.2019.03.003. [Epub ahead of print]


Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.

Minner S, Hager D, Steurer S, Höflmayer D, Tsourlakis MC, Möller-Koop C, Clauditz TS, Hube-Magg C, Luebke AM, Simon R, Sauter G, Göbel C, Weidemann S, Lebok P, Dum D, Fraune C, Izbicki J, Burandt E, Schlomm T, Huland H, Heinzer H, Haese A, Graefen M, Heumann A.

Neoplasia. 2019 Sep;21(9):872-881. doi: 10.1016/j.neo.2019.07.003. Epub 2019 Aug 2.


Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer.

Preisser F, Nazzani S, Mazzone E, Marchioni M, Bandini M, Tian Z, Haese A, Saad F, Zorn K, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI.

Clin Genitourin Cancer. 2019 May 27. pii: S1558-7673(19)30160-0. doi: 10.1016/j.clgc.2019.05.022. [Epub ahead of print]


The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer.

Büscheck F, Zub M, Heumann A, Hube-Magg C, Simon R, Lang DS, Höflmayer D, Neubauer E, Jacobsen F, Hinsch A, Luebke AM, Tsourlakis MC, Sauter G, Huland H, Graefen M, Haese A, Heinzer H, Schlomm T, Clauditz TS, Burandt E, Wilczak W, Steurer S, Minner S.

Tumour Biol. 2019 Jul;41(7):1010428318824815. doi: 10.1177/1010428318824815.


NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study.

Dinneen E, Haider A, Allen C, Freeman A, Briggs T, Nathan S, Brew-Graves C, Grierson J, Williams NR, Persad R, Oakley N, Adshead JM, Huland H, Haese A, Shaw G.

BMJ Open. 2019 Jun 11;9(6):e028132. doi: 10.1136/bmjopen-2018-028132.


Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.

Mandel PC, Huland H, Tiebel A, Haese A, Salomon G, Budäus L, Tilki D, Chun F, Heinzer H, Graefen M, Pantel K, Riethdorf S, Steuber T.

Eur Urol Focus. 2019 Jun 6. pii: S2405-4569(19)30145-2. doi: 10.1016/j.euf.2019.05.008. [Epub ahead of print]


Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy.

Klippenstein P, Schlomm T, von Amsberg G, Beyer B, Pompe RS, Michl U, Salomon G, Thederan I, Budäus L, Heinzer H, Tilki D, Haese A, Huland H, Graefen M, Steuber T, Tennstedt P.

Urol Oncol. 2019 Sep;37(9):575.e1-575.e7. doi: 10.1016/j.urolonc.2019.04.007. Epub 2019 Apr 30.


SNW1 is a prognostic biomarker in prostate cancer.

Höflmayer D, Willich C, Hube-Magg C, Simon R, Lang D, Neubauer E, Jacobsen F, Hinsch A, Luebke AM, Tsourlakis MC, Huland H, Graefen M, Haese A, Heinzer H, Minner S, Büscheck F, Sauter G, Schlomm T, Steurer S, Clauditz TS, Burandt E, Wilczak W, Bernreuther C.

Diagn Pathol. 2019 May 1;14(1):33. doi: 10.1186/s13000-019-0810-8.


Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.

Haese A, Trooskens G, Steyaert S, Hessels D, Brawer M, Vlaeminck-Guillem V, Ruffion A, Tilki D, Schalken J, Groskopf J, Van Criekinge W.

J Urol. 2019 Aug;202(2):256-263. doi: 10.1097/JU.0000000000000293. Epub 2019 Jul 8.


Neural correlates of feedback processing during a sensory uncertain speech - nonspeech discrimination task.

Ludowicy P, Czernochowski D, Weis T, Haese A, Lachmann T.

Biol Psychol. 2019 May;144:103-114. doi: 10.1016/j.biopsycho.2019.03.017. Epub 2019 Mar 30.


Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young men ≤ 45 years of age.

Tilki D, Maurer V, Pompe RS, Chun FK, Preisser F, Haese A, Graefen M, Huland H, Mandel P.

World J Urol. 2019 Apr 2. doi: 10.1007/s00345-019-02740-8. [Epub ahead of print]


A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures.

Haese A, Knipper S, Isbarn H, Heinzer H, Tilki D, Salomon G, Michl U, Steuber T, Budäus L, Maurer T, Tennstedt P, Huland H, Graefen M.

BJU Int. 2019 Jun;123(6):1031-1040. doi: 10.1111/bju.14760. Epub 2019 Apr 12.


Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment.

Beckmann A, Spalteholz J, Langer F, Heinzer H, Budäus L, Tilki D, Michl U, Soave A, Steuber T, Veleva V, Salomon G, Haese A, Huland H, Graefen M, Isbarn H.

World J Urol. 2019 Feb 6. doi: 10.1007/s00345-019-02668-z. [Epub ahead of print]


[Robot-assisted and open radical prostatectomy achieve equal outcomes].

Knipper S, Haese A.

Urologe A. 2019 Mar;58(3):319-320. doi: 10.1007/s00120-018-0837-6. German. No abstract available.


Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.

Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C.

Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14.


A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.

Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, Leung CH, Casale P, Chiang CH, Tan LG, Chiong E, Huang CY, Wu HC, Nieboer D, Ye DW, Bangma CH, Roobol MJ.

Eur Urol. 2019 Apr;75(4):558-561. doi: 10.1016/j.eururo.2018.10.047. Epub 2018 Nov 2.


Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States.

Preisser F, Nazzani S, Mazzone E, Knipper S, Bandini M, Tian Z, Haese A, Saad F, Zorn KC, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI.

World J Urol. 2019 Jul;37(7):1305-1313. doi: 10.1007/s00345-018-2525-y. Epub 2018 Oct 12.


Supplemental Content

Loading ...
Support Center